uniQure N.V. Net Income (Loss) Available to Common Stockholders, Basic
uniQure N.V. (QURE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$198.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-02
- uniQure N.V. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$43.64M.
- uniQure N.V. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$73.26M.
- uniQure N.V. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$44.38M.
- uniQure N.V. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$56.30M.
- uniQure N.V. net income (loss) available to common stockholders, basic for fiscal 2025 was -$198.97M.
- uniQure N.V. net income (loss) available to common stockholders, basic for fiscal 2024 was -$239.56M.
- uniQure N.V. net income (loss) available to common stockholders, basic for fiscal 2023 was -$308.48M.
- uniQure N.V. net income (loss) available to common stockholders, basic for fiscal 2022 was -$126.79M, a 138.47% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$198.97M 10-K · filed 2026-03-02 | |||
| 2025-03-31 | -$43.64M 10-Q · filed 2025-05-09 | -$116.90M derived: sum of 2 quarters · filed 2026-03-02 | -$161.28M derived: sum of 3 quarters · filed 2026-03-02 | -$217.57M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$73.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$117.64M derived: sum of 2 quarters · filed 2026-03-02 | -$173.94M derived: sum of 3 quarters · filed 2026-03-02 | -$239.56M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$44.38M 10-Q · filed 2024-11-05 | -$100.68M derived: sum of 2 quarters · filed 2024-11-05 | -$166.29M 10-Q · filed 2024-11-05 | -$239.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$56.30M 10-Q · filed 2024-08-01 | -$121.92M 10-Q · filed 2024-08-01 | -$195.12M derived: sum of 3 quarters · filed 2026-03-02 | -$284.69M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$65.62M 10-Q · filed 2025-05-09 | -$138.82M derived: sum of 2 quarters · filed 2026-03-02 | -$228.40M derived: sum of 3 quarters · filed 2026-03-02 | -$296.87M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$73.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$162.78M derived: sum of 2 quarters · filed 2026-03-02 | -$231.25M derived: sum of 3 quarters · filed 2026-03-02 | -$308.48M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$89.57M 10-Q · filed 2024-11-05 | -$158.04M derived: sum of 2 quarters · filed 2024-11-05 | -$235.27M 10-Q · filed 2024-11-05 | -$228.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$68.47M 10-Q · filed 2024-08-01 | -$145.70M 10-Q · filed 2024-08-01 | -$138.89M derived: sum of 3 quarters · filed 2025-02-27 | -$186.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$77.23M 10-Q · filed 2024-05-07 | -$70.42M derived: sum of 2 quarters · filed 2025-02-27 | -$118.28M derived: sum of 3 quarters · filed 2025-02-27 | -$157.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$41.05M derived: sum of 2 quarters · filed 2025-02-27 | -$80.11M derived: sum of 3 quarters · filed 2025-02-27 | -$126.79M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$47.86M 10-Q · filed 2023-11-07 | -$86.92M derived: sum of 2 quarters · filed 2023-11-07 | -$133.60M 10-Q · filed 2023-11-07 | -$125.39M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$39.06M 10-Q · filed 2023-08-01 | -$85.74M 10-Q · filed 2023-08-01 | -$77.53M derived: sum of 3 quarters · filed 2024-02-28 | -$114.06M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$46.68M 10-Q · filed 2023-05-09 | -$38.47M derived: sum of 2 quarters · filed 2024-02-28 | -$75.00M derived: sum of 3 quarters · filed 2024-02-28 | $324.47M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$28.32M derived: sum of 2 quarters · filed 2024-02-28 | $371.14M derived: sum of 3 quarters · filed 2024-02-28 | $329.59M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$36.53M 10-Q · filed 2022-11-02 | $362.94M derived: sum of 2 quarters · filed 2022-11-02 | $321.38M 10-Q · filed 2022-11-02 | $320.68M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $399.47M 10-Q · filed 2022-08-08 | $357.91M 10-Q · filed 2022-08-08 | $357.21M derived: sum of 3 quarters · filed 2023-02-27 | $303.44M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$41.56M 10-Q · filed 2022-05-02 | -$42.26M derived: sum of 2 quarters · filed 2023-02-27 | -$96.03M derived: sum of 3 quarters · filed 2023-02-27 | -$138.58M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$54.47M derived: sum of 2 quarters · filed 2023-02-27 | -$97.03M derived: sum of 3 quarters · filed 2023-02-27 | -$125.02M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$53.77M 10-Q · filed 2021-10-25 | -$96.33M derived: sum of 2 quarters · filed 2021-10-25 | -$124.33M 10-Q · filed 2021-10-25 | -$165.75M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$42.55M 10-Q · filed 2021-07-26 | -$70.55M 10-Q · filed 2021-07-26 | -$111.98M derived: sum of 3 quarters · filed 2022-02-25 | -$135.58M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$28.00M 10-Q · filed 2021-05-10 | -$69.42M derived: sum of 2 quarters · filed 2022-02-25 | -$93.03M derived: sum of 3 quarters · filed 2022-02-25 | -$124.43M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$41.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$65.03M derived: sum of 2 quarters · filed 2022-02-25 | -$96.43M derived: sum of 3 quarters · filed 2022-02-25 | -$124.20M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$23.60M 10-Q · filed 2020-10-27 | -$55.00M derived: sum of 2 quarters · filed 2020-10-27 | -$82.78M 10-Q · filed 2020-10-27 | -$104.66M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$31.40M 10-Q · filed 2020-07-30 | -$59.17M 10-Q · filed 2020-07-30 | -$81.06M derived: sum of 3 quarters · filed 2021-03-01 | -$103.09M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$27.77M 10-Q · filed 2020-04-29 | -$49.66M derived: sum of 2 quarters · filed 2021-03-01 | -$71.69M derived: sum of 3 quarters · filed 2021-03-01 | -$92.29M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$43.92M derived: sum of 2 quarters · filed 2021-03-01 | -$64.52M derived: sum of 3 quarters · filed 2021-03-01 | -$83.30M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$22.04M 10-Q · filed 2019-10-28 | -$42.63M derived: sum of 2 quarters · filed 2019-10-28 | -$61.42M 10-Q · filed 2019-10-28 | -$88.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$20.59M 10-Q · filed 2019-07-29 | -$39.38M 10-Q · filed 2019-07-29 | -$66.86M derived: sum of 3 quarters · filed 2020-03-02 | -$77.10M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$18.79M 10-Q · filed 2019-04-29 | -$46.26M derived: sum of 2 quarters · filed 2020-03-02 | -$56.51M derived: sum of 3 quarters · filed 2020-03-02 | -$77.78M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$27.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$37.72M derived: sum of 2 quarters · filed 2020-03-02 | -$58.99M derived: sum of 3 quarters · filed 2020-03-02 | -$79.26M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$10.24M 10-Q · filed 2018-11-06 | -$31.51M derived: sum of 2 quarters · filed 2018-11-06 | -$51.79M 10-Q · filed 2018-11-06 | -$66.51M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$21.27M 10-Q · filed 2018-08-08 | -$41.54M 10-Q · filed 2018-08-08 | -$56.26M derived: sum of 3 quarters · filed 2019-02-28 | -$71.54M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$20.27M 10-Q · filed 2018-04-30 | -$34.99M derived: sum of 2 quarters · filed 2019-02-28 | -$50.27M derived: sum of 3 quarters · filed 2019-02-28 | -$71.35M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | -$14.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$30.00M derived: sum of 2 quarters · filed 2019-02-28 | -$51.08M derived: sum of 3 quarters · filed 2019-02-28 | -$73.37M 10-K · filed 2019-02-28 |
| 2016-09-30 | -$15.27M 10-Q · filed 2017-11-01 | -$36.35M derived: sum of 2 quarters · filed 2017-11-01 | -$58.65M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | -$21.08M 10-Q · filed 2017-08-08 | -$43.38M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | -$22.30M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | -$82.08M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | -$49.78M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |